Flow of Progress: Optimizing Current Treatment Strategies and the Pharmacist’s Role in Benign Prostatic Hyperplasia

Author: Shilpa Amara, PharmD

Flow of Progress: Optimizing Current Treatment Strategies and the Pharmacist’s Role in Benign Prostatic Hyperplasia

Shilpa Amara, PharmD
Drug Information Specialist
Barnabas Health
West Orange, New Jersey
 
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.
 
Faculty
Shilpa Amara, PharmD
 
Pharmacy Times Office of Continuing Professional Education
Planning Staff—Judy V. Lum, MPA, and Steve Lin, PharmD
 
Pharmacy Times Editorial Staff
Kirk McKay and David Allikas
 
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
 
LEARNING Objectives:
Upon completion of this educational activity, participants should be able to:
  1. Discuss the epidemiology and pathophysiology of benign prostatic hyperplasia(BPH).
  2. Recognize the impact of BPH on patients and their quality of life.
  3. Examine current treatment strategies for the management of BPH, including special considerations in managing comorbidities.
  4. Discuss the pharmacist’s role in managing BPH, including addressing treatment expectations, medication safety, and patient compliance.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: November 12, 2013
Expiration date: November 12, 2015
Estimated time to complete activity: 2 hours

Click here to view this activity.

This activity is supported by an educational grant from Watson Laboratories, Inc.
 
Description: Description: harmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-13-159-H01-P. The activity is available for CE credit through November 12, 2015.